The effect of nirmatrelvir-ritonavir on short- and long-term adverse outcomes from COVID-19 among patients with kidney disease
On Dec. 31, 2024, a study was published of patients with kidney disease who are at high risk for adverse outcomes after COVID-19 despite vaccination. Because patients with advanced chronic kidney disease (CKD) and kidney failure were excluded from registrational trials, the impact of the protease inhibitor nirmatrelvir-ritonavir in patients with kidney disease is unknown.
A cohort study evaluated adverse outcomes in patients with kidney disease who developed COVID-19. Patients prescribed nirmatrelvir-ritonavir for COVID-19 between March 16, 2022–November 30, 2022 were propensity-score matched to comparators diagnosed with COVID-19 between July 15, 2021–March 15, 2022 (prior to the use of nirmatrelvir-ritonavir in our healthcare network).
The researchers concluded that nirmatrelvir-ritonavir was associated with decreased risk of hospitalization within 30 days and 1-year risk of MACE and death in patients with CKD and kidney failure.
Tags:
Source: Oxford Academic
Credit: Image: Scanning electron microscope image shows SARS-CoV-2 (magenta objects) emerging from the surface of cells cultured in the lab. SARS-CoV-2. Credit: Rocky Moutain Laboratory, National Institute of Allergy and Infectious Diseases.
